| http://linkedlifedata.com/r... | rdf:type | entrezgene:Interaction | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:1967269 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:1978941 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:2543930 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:2846691 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:7541827 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:8168144 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:15784911 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:8450224 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:12427289 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:8084338 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:3489470 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:7602119 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:8376762 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:9079699 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:1869305 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:7512597 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:10729169 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:1970352 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:7645219 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:7734415 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:interactant | entrez-gene:155971 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:geneRifText | Antibodies against cell surface molecules LFA-1, ICAM-1, HLA-DR, and CD28 inhibit the HIV-1 gp160-induced B cell differentiation response; gp160 also induces IL-6R and CD23 molecule expression on B cells | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:geneRifText | Soluble HIV-1 gp41 can selectively enhance MHC class I and II expression on human B cells, but does not increase expression of other cell surface antigens such as CD21 and CD54 (ICAM-1) | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:geneRifText | Soluble HIV-1 gp41 enhancement effects on MHC class I and II antigen expression can be inhibited by soluble gp41-binding proteins of 45, 49 and 62 kD from human B cells | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:geneRifText | Processing of HIV-1 gp160 to gp120 and gp41 is necessary for the association of HIV-1 envelope glycoproteins with class II MHC | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:geneRifText | Amino acid residues 42-49 in the V1 region of CD4 are involved in the interaction between HIV-1 gp120 and class II major histocompatibility complex molecules | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:geneRifText | HIV envelope protein gp120 can specifically inhibit CD4-dependent class II MHC-restricted T cell response to Ag | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:geneRifText | A 43-amino-acid sequence between amino acids 708 and 750 in the HIV-1 gp41(TM) cytoplasmic tail is required for efficient incorporation of HLA class II proteins into virions | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:geneRifText | Genetic variability in HIV-1 gp120 affects its interactions with HLA-DR molecules and T cell receptor | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:geneRifText | CD4+ T cells infected with CCR5-tropic HIV-1 have significantly higher levels of activation-marker expression (e.g. CD25, CD71 and HLA-DR) than CD4+ T lymphocytes infected with CXCR4-tropic HIV-1 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:keyphrase | inhibits | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:keyphrase | interacts with | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:keyphrase | upregulates | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:keyphrase | associates with | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:keyphrase | incorporates | lld:entrezgene |
| entrez-gene:3126 | entrezgene:interaction | http://linkedlifedata.com/r... | lld:entrezgene |
